Immunology-focused Windward Bio raised a mega-round of financing to support a lead program in development for respiratory disorders and a second program that could find use in respiratory and dermatological indications. Both drugs are long-acting antibodies that offer a dosing edge over currently available biologic medicines.
The post Windward Bio Secures $165M for Clinical Trials in Asthma, COPD & More appeared first on MedCity News.
